newsfilter
← Latest News
GlobeNewswire·

Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

- First patient dosed in Phase 1b/2a clinical trial of AJ201; topline data anticipated in first half of 2024 - - Positive BAER-101 preclinical data demonstrate excellent anti-seizure activity in translational animal